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Abstract Human synthetic islet amyloid polypeptide (hIAPP)
is rapidly converted to L-sheet conformation and fibrils in
aqueous media. Optimal solubility conditions for hIAPP were
determined by circular dichroism spectroscopy and transmission
electron microscopy. hIAPP in trifluoroethanol or hexafluoro-2-
isopropanol (HFIP) diluted in water or phosphate buffer (PB)
exhibited random structure which was converted to L-sheet and
fibrils with time. hIAPP, solubilised in HFIP, filtered and
lyophilised remained in stable random structure for up to 7 days
in water; in PB, insoluble aggregates precipitated from which
protofilaments and fibrils formed with time. This suggests that
amorphous aggregates of hIAPP could initiate islet amyloidosis
in vivo.
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1. Introduction
Islet amyloid polypeptide (IAPP), amylin, is a 37 amino
acid peptide which forms amyloid ¢brils in pancreatic islets
in type 2 diabetes [1,2]. The mechanisms promoting conver-
sion of soluble monomeric IAPP into L conformation and
¢bril formation are largely unclear. Rodent IAPP, which dif-
fers from the human sequence in only six residues, is not
amyloidogenic; this has been ascribed to the substitution of
proline residues in the region IAPP20ÿ29 [3^5]. In vitro inves-
tigations into the secondary structure of human IAPP and
identi¢cation of the structural changes that accompany amy-
loid ¢bril formation have been hampered by the rapid con-
version of the peptide into ¢brils in aqueous media [6,7]. Re-
ports of secondary structure of human IAPP have been
inconsistent and have utilised material from di¡erent sources
and prepared under varied conditions; overall these studies
suggest that human synthetic IAPP, when prepared in aque-
ous medium, assumes a largely L conformation and oligomer-
ises whereas the more soluble rat IAPP is in random confor-
mation [6^9]. However, when human IAPP was prepared in
hexa£uoroisopropanol (HFIP), a random conformation was
observed which was rapidly converted to L conformation by
‘seeding’ with preformed ¢brils [10,11].
Some of the di⁄culties encountered in attempting to repro-
duce the many and varied proposed physiological and cyto-
toxic e¡ects of IAPP with synthetic peptide may have resulted
from the di⁄culty in maintaining human IAPP in a stable
monomeric conformation. To establish a reproducible method
of preparation of human IAPP so that the peptide is in a
stable molecular structure and can be used in physiological
experiments, the molecular conformation and stability of dif-
ferent preparations of human IAPP have been studied by
circular dichroism (CD) spectroscopy and ¢bril formation
by electron microscopy and thio£avine T £uoroscopy.
2. Materials and methods
2.1. Secondary structure predictions of human and rat IAPP
Di¡erent algorithms were used for prediction of secondary structure
of human IAPP1ÿ37 and rat IAPP1ÿ37. These methods included double
prediction [12], GOR4 [13], HNNC, SIMPA96 [14], SOPM [15] and
Sec Cons.
2.2. Preparation of peptide solutions for examination of molecular
structure
Human IAPP lyophilised from tri£uoroacetic acid was obtained
from Bachem (Torrance, CA, USA) or Peninsula Laboratories (St
Helens, UK). Rat IAPP (Bachem) and the Alzheimer’s peptide
AL1ÿ42 (Bachem) were also examined as controls. Peptides were pre-
pared in £uorinated alcohols (1 mg/ml) and molecular structures com-
pared in diluted alcohols, in water or phosphate bu¡er (PB). Com-
mercial samples of peptides were reconstituted either (i) in 60% 2,2,2-
tri£uoroethanol (TFE) (Sigma, Poole, UK) in water; or (ii) in 100%
1,1,1,3,3,3-hexa£uoro-2-isopropanol (HFIP) (Sigma). Aliquots were
either examined directly in diluted samples or freeze dried and recon-
stituted in TFE, HFIP, dH2O or in 10 mM PB, pH 7.0. To further
purify the peptide, some samples dissolved in HFIP were ¢ltered
(0.2 Wm) before lyophilisation.
2.3. CD spectroscopy
Aliquots of peptide solutions (200 Wl) were examined over 190^
250 nm wavelength, in quartz cuvettes with a 1 mm path length in
a Jasco J720 spectropolarimeter. The photomultiplier voltage was
monitored to ensure that the samples were transparent. Baseline spec-
tra (solvent only) were subtracted from collected data.
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2.4. Electron microscopy
Peptide preparations were supported on carbon- and formvar-
coated grids and negatively stained with 2% uranyl acetate. Grids
were examined with a Joel 1010 microscope, accelerating voltage
80 kV.
2.5. Thio£avine T spectroscopy
Samples of peptide in bu¡er (800 Wl) were mixed with 10 Wl thio-
£avine T (Th T) (1 M, Sigma, 20% dye content) and aliquots of the
mixture examined over a 10-min period at an excitation wavelength of
350 or 450 nm and emission spectra collected at 400^500 nm in a
spectro£uorometer (Perkin Elmer). Peaks of emission for unbound
Th T were observed at 438 nm and at 482 nm for thio£avine bound
to ¢brils. Background readings from control solutions were sub-
tracted. To determine conditions for optimal Th T binding to IAPP
¢brils, ¢bril mixtures were examined at di¡erent pHs in 10 mM citrate
bu¡er, pH 4, 10 mM PB, pH 7.4, 10 mM glycine^NaOH at pH 9 and
10.6.
3. Results
3.1. Secondary structure predictions
The di¡erent methods of structure prediction produced
some common features (Fig. 1). The double prediction meth-
od (Fig. 1a, 1) indicated that human IAPP had a random
sequence at the N-terminus followed by a helical segment;
the short extended L-strand was predicted to extend to His18
and was separated from the longer L-strand in the region
IAPP26ÿ29 by a random conformation. These two L-strand
regions were a feature of all but one of the predictions. A L
turn was proposed by two systems in the region of IAPP20
(Fig. 1a, 1,6). Rat IAPP had a similar helical segment towards
the N-terminus in all predictions but the proline residues at
positions 24, 27 and 29 appear to disrupt the propensity for
L-strand in this region (Fig. 1b).
3.2. Structural features of hIAPP solubilised in 60% TFE
compared with rIAPP and AL
To improve the solubility and stability of hIAPP, the
commercially supplied peptide (Bachem) was reconstituted in
60% TFE and freeze dried. TFE at high concentrations can
promote helical structure and reduce the tendency for conver-
sion to L-sheet and formation of insoluble ¢brils [16,17]. The
maximal proportion of TFE for hIAPP solubility was 60%
and IAPP in this solvent was compared with IAPP in water.
Dissolution of aliquots at 26 WM in either 60% TFE or in
dH2O resulted in a spectrum with a minimum at 221 nm
and a shoulder at 207 nm (Fig. 2). These features suggest a
mixture of K-helical and L conformation. The samples were
examined over a 24-h period (incubation at 20‡C) when there
was a progressive increase in the maximum at 196 nm and a
further increase in the minimum which became closer to
218 nm (Fig. 2a). When prepared in 60% TFE human IAPP
precipitated from solution over a 1-week period (Fig. 2b).
Human IAPP (26 WM) from Peninsula Laboratories prepared
by the same method as above exhibited a similar spectrum but
with low amplitude suggesting that much lower concentra-
tions of peptide were available for analysis compared to those
seen with peptide obtained from Bachem. For comparison, rat
IAPP1ÿ37 and AL1ÿ42 were reconstituted and solubilised in
60% TFE or dH2O as above. Rat IAPP dissolved in water
showed a largely random structure but the minimum was at
201 nm suggesting a partly helical component (Fig. 2c) where-
Fig. 1. Representation of secondary structure predictions for (a) human IAPP and (b) rat IAPP. Algorithms used: 1, double prediction;
2, GOR4; 3, HNNC; 4, Predator; 5, SIMPA96; 6, SOPM; 7, Sec Cons. Amino acid sequence of human IAPP (a) and rat IAPP (b) is indi-
cated by single letter code.
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as a classical helical spectrum was observed in 60% TFE:
these conformations did not change after 7 days incubation
at 20‡C. Fibrils were visible by transmission electron micros-
copy (TEM) at all time points in mixtures of hIAPP in 60%
TFE or dH2O, or in aliquots of AL1ÿ42 after 24 h incubation:
these ¢brils were straight and unbranching with a diameter of
5^10 nm. However, no ¢brils or precipitate were present in the
rat IAPP solutions.
Fig. 2. CD spectra of human or rat IAPP prepared in water (a,c) or TFE (b,d) or solubilised in HFIP and reconstituted in 1% HFIP, water or
PB (e^g). a: 26 WM hIAPP (Bachem) in dH2O at (i) time zero, solid line, (ii) 2 h, dotted line, (iii) 8 h, dashed line and (iv) 24 h showing a
mixture of K-helix and L conformation but an increase in the L conformation with time. b: 26 WM hIAPP reconstituted in 60% TFE measured
over 1 week: (i) time zero, solid line, (ii) 6 h, (iii) 7 days showing that the peptide comes out of solution progressively. c: Spectrum of rat
IAPP dissolved in dH2O after 7 days incubation showing largely random conformation. d: Spectrum of hIAPP prepared and dissolved in 10%
HFIP after 7 days incubation exhibiting a largely helical conformation. e: 12 WM hIAPP in 1% HFIP in PB (i) time zero, solid line, (ii) 10 min,
dotted line, (iii) 30 min, dashed line, (iv) 3 h, dash-dotted line; this was a less stable preparation and was gradually converted from K to L with
time. f: 12 WM hIAPP freeze dried from ¢ltered 100% HFIP and reconstituted in water: (i) time zero and (ii) after 7 days, dotted line, showing
that the peptide is in a stable random conformation. g: 12 WM hIAPP freeze dried from ¢ltered 100% HFIP and reconstituted in PB: (i) time
zero, solid line, (ii) 1.5 h, dotted line, (iii) 3 h, dashed line, (iv) 24 h, dash-dotted line; the peptide gradually precipitated from the solution
without any evidence of conversion to a L conformation.
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3.3. E¡ect of solubilisation of hIAPP with HFIP
Since hIAPP was soluble in 100% HFIP this was potentially
a more e¡ective solvent than TFE to maintain helical confor-
mation and prevent ¢bril formation [18,19]. hIAPP (65 WM)
solubilised in 100% HFIP and diluted to 10% HFIP in dH2O
(6.5 WM hIAPP) exhibited a largely helical spectrum. The
molecular structure of hIAPP in 10% HFIP was stable, in a
largely helical conformation, after a 1-week incubation at
20‡C (Fig. 2d) and no ¢brils were detected with TEM. hIAPP
in 1% HFIP in PB was less stable and conversion to a mixture
of helix and L structure via a random conformation was ap-
parent after 30 min incubation (Fig. 2e).
However, 1% HFIP is toxic to cultured cells so this method
of IAPP preparation is not suitable for physiological exper-
imentation, therefore the e¡ects of excluding HFIP from the
¢nal mixture were determined. A ¢ltration step (0.2 Wm ¢lters)
was introduced to remove potential ‘seeds’ for aggregation
[11,20]. Following reconstitution of hIAPP (Bachem) in
100% HFIP and ¢ltration, aliquots of hIAPP were freeze
dried to remove the HFIP. These were then prepared in water
(pH 7.3) or PB (pH 7.5) at 6.5 WM. In dH2O, hIAPP exhibited
a random spectrum with slight helical properties (Fig. 2f); this
spectrum remained unchanged in characteristics or amplitude
over the 7 days of examination and ¢brils were not seen by
TEM at any time point. Samples prepared in PB had a similar
structure to those in dH2O but the spectra were not stable
with incubation: there was almost complete loss of signal
after 24 h at 20‡C (Fig. 2g) without evidence of a change to
Fig. 3. Development of ¢brils from aggregates of hIAPP precipitated in PB. a^c: Electron micrographs of negatively stained preparations of hI-
APP lyophilised from HFIP and reconstituted in PB (a), after 60 min when small proto¢laments were forming from the aggregates (b), after
180 min when there was a mixture of amorphous and proto¢laments (c) and at 24 h when the aggregates had been completely replaced by ¢-
brils (d). pH dependence of Th T binding to ¢brils of hIAPP (upper panel) and AL1ÿ42 (6 WM) and (lower panel) time course of ¢bril forma-
tion of hIAPP lyophilised from HFIP and reconstituted in PB, same preparations as in a^c, mean þ S.E.M., n = 3.
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L conformation. Samples prepared in PB contained amor-
phous protein aggregates visible by TEM at the initial time
point but there was no evidence of ¢brils (Fig. 3). After 1 h
incubation the aggregates increased in density but occasional
¢ne proto¢laments were visible (Fig. 3a,b) which increased in
number over the following hours and, at 24 h, the preparation
contained predominantly ¢brils with the typical amyloid char-
acteristics (Fig. 3c). Thus, IAPP can be in a stable unfolded
state in water at neutral pH in the absence of ‘seeds’. How-
ever, addition of phosphate salts promoted precipitation into
amorphous aggregates and eventually ¢bril formation.
3.4. Examination of ¢bril formation with thio£avine
T £uorescence
Further evidence of precipitation as amorphous aggregates
came from samples prepared in PB and examined by Th T
£uorescence to quantify ¢bril formation. To optimise the con-
ditions for binding of Th T to IAPP ¢brils, the pH depen-
dence of binding was determined with a standard mixture of
IAPP ¢brils and compared with a ¢bril-containing prepara-
tion of AL1ÿ42 (1 mg/ml). Samples of AL1ÿ42 and hIAPP (0.26,
1.5, 3 and 6 WM) were examined in the absence of Th T to
determine the contribution of light scattering to the signal.
This was proportional to the concentration of peptide but
similar at all pHs examined. Whereas the binding of Th T
to AL1ÿ42 increased with a change in pH from 4 to 11 there
was no pH dependence for Th T binding to hIAPP (Fig. 3d).
Subsequent experiments were made at pH 9.0 to be consistent
with other reports [22^24]. Samples of hIAPP prepared in PB
from the HFIP-¢ltered and solubilised stock (as examined
above with CD) (50 Wg/ml) exhibited no signi¢cant £uores-
cence at time zero indicating the absence of ¢brils. However,
the Th T binding gradually increased, reaching a maximum
after 24 h incubation (Fig. 3e). This corresponds to the elec-
tron microscopic observations of no ¢brils at time zero fol-
lowed by ¢bril growth from amorphous aggregates over this
time period.
4. Discussion
These data suggest that synthetic human IAPP can exist in
a stable, largely random conformation in aqueous medium
when all potential ‘seeding’ material has been removed. In
phosphate bu¡er, hIAPP precipitated as amorphous aggre-
gates without observable ¢bril formation. Proto¢laments de-
veloped from these aggregates to form typical amyloid ¢brils
over periods of time.
Previously reported secondary structure predictions for hI-
APP1ÿ37 have indicated a short region of propensity for
L-strand in the region IAPP25ÿ29 [6,10]. The majority of pre-
dictions for rat IAPP show no evidence for substantial regions
of L-strand either in the amino acid substituted region,
IAPP20ÿ29, or in the region homologous with the human pep-
tide, IAPP13ÿ16. However, such predictions are suggestions
only and folding studies and crystal structure analyses are
required to con¢rm molecular conformation.
TFE is known to promote K-helical tendencies by a¡ecting
intra-molecular hydrogen bonding and destabilising tertiary
contacts [17,19]. It was therefore examined as a solvent to
create a soluble state of hIAPP which did not form ¢brils
immediately. Whereas rat IAPP and AL peptide were con-
verted from a random conformation to classical K-helices
when solubilised in 60% TFE, the L structure of hIAPP was
unchanged and ¢brils were present at all time points. This is
consistent with the data of Hubbard et al. [7] ; however, there
was no evidence for a large, 98%, K-helical contribution as
described previously [9]. Di¡erences between reported data
and the present results may re£ect the relative proportions
of monomeric, oligomeric and ¢brillar peptide that are
present in the CD cuvette under conditions of ¢bril forma-
tion; the di¡erent proportions of these oligomers in a mixture
could account for the many di¡erent structures that have been
reported for hIAPP prepared in water or in TFE.
hIAPP was more soluble in HFIP than in TFE and in 100%
HFIP produced an K-helical signal which was stable over
many days. Reduction of the proportion of HFIP to 1% in
PB destabilised the molecule which was initially converted to
a more random structure as has been described previously
[11,21] and ¢nally to a L structure with the appearance of
¢brils after 24 h incubation. Filtration of the peptide in
HFIP before freeze drying removed material s 0.2 Wm which
could act as ‘seeds’ for initiation of ¢bril formation [20,21].
Amino acid analyses demonstrated that less than 10% of the
original concentration of peptide was removed by ¢ltration;
this indicated that the absence of ¢brils when reconstituted in
water was not as a result of a reduction in concentration.
Thus synthetic hIAPP, like rat IAPP and the homologous
peptide, calcitonin gene-related peptide [7], can exist in a sta-
ble random structure in the absence of material which has the
potential to seed the ¢bril-forming reaction. From this con-
formation, a degree of unfolding and refolding would be re-
quired during the process of amyloid ¢bril formation. Unfold-
ing of hIAPP has been described under strong denaturing
conditions (6 M GdnHCl) and at high temperatures (60‡C)
[21] ; under moderate reducing conditions, a population of
IAPP in partially folded states has been described which rap-
idly forms ¢brils. However, the process by which hIAPP is
converted to ¢brils from stable monomeric form remains un-
clear.
When hIAPP (lyophilised and ¢ltered but in the absence of
the stabilising 1% HFIP) was reconstituted in PB, the peptide
initially exhibited a random conformation as in water. How-
ever, over a 24-h period, the peptide precipitated out of solu-
tion without exhibiting, at any time, a L-sheet conformation
or any other intermediate form as has been suggested for
other amyloidogenic peptides [25]. The amorphous aggregate
resulting from this precipitation was visible by TEM. The very
¢ne (V6 nm diameter) proto¢laments that formed amongst
this precipitate could represent the very earliest stages of ¢bril
formation. This process, which was con¢rmed by Th T £uo-
rescence, increased with time so that, by 24 h, classical amy-
loid ¢brils had replaced the aggregate.
These data suggest that hIAPP can exist in a stable random
form in aqueous media in the absence of ‘seeds’ but will pre-
cipitate, as an unstructured aggregate which in turn creates a
favourable microenvironment for conversion of hIAPP to
L-sheet and proto¢lament formation. This sequence of events
could be analogous to changes occurring in the deposition of
islet amyloid and in other amyloidoses in vivo: amorphous
accumulations of peptide (possibly not in L conformation)
have been described as an early step in the process of ¢brillo-
genesis in pancreatic islets [26] and in Alzheimer’s disease [27].
These accumulations could form the matrix for proto¢lament
formation and assembly of ¢brils in vivo.
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